Antagonistic variant virus prevents wild-type virus-induced lethal immunopathology

Journal of Experimental Medicine

Volumn 196, Issue 8, 2002, Pages 1039-1046

  Hunziker, Lukas ^a   Recher, Mike ^a   Ciurea, Adrian ^a   Martinic, Marianne M A ^a   Odermatt, Bernhard ^a   Hengartner, Hans ^a   Zinkernagel, Rolf M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antagonistic peptide; APL; CD4+ T cells; LCMV; Protection

Indexed keywords

CD8 ANTIGEN; EPITOPE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERINFECTION; SURVIVAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VIRUS CARRIER; VIRUS TYPING; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL;

EID: 0037152161     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20012045     Document Type: Article

References (29)

1. Sloan-Lancaster, J., and P.M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1-27.
2. Evavold, B.D., and P.M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1308-1310.
3. De Magistris, M.T., J. Alexander, M. Coggeshall, A. Altman, F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:625-634.
4. Sloan-Lancaster, J., B.D. Evavold, and P.M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 363:156-159.
5. Racioppi, L., F. Ronchese, L.A. Matis, and R.N. Germain. 1993. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 177:1047-1060.
6. Madrenas, J., R.L. Wange, J.L. Wang, N. Isakov, L.E. Samelson, and R.N. Germain. 1995. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science. 267:515-518.
7. Nicholson, L.B., J.M. Greer, R.A. Sobel, M.B. Lees, and V.K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 3:397-405.
8. Karin, N., D.J. Mitchell, S. Brocke, N. Ling, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production. J. Exp. Med. 180:2227-2237.
9. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:343-346.
10. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6:1176-1182.
11. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J.A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-1175.
12. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. Edwards, et al. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 369:403-407.
13. Allen, P.M., and R.M. Zinkernagel. 1994. Promethean viruses? Nature. 369:355-356.
14. Bertoletti, A., A. Sette, F.V. Chisari, A. Penna, M. Levrero, and M. De Carli. 1994. Natural variants of cytotoxic epitopes are T cells receptor antagonists for anti-viral cytotoxic T cells. Nature. 369:407-410.
15. Tsai, S.L., Y.M. Chen, M.H. Chen, C.Y. Huang, I.S. Sheen, C.T. Yeh, J.H. Huang, G.C. Kuo, and Y.F. Liaw. 1998. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 115:954-965.
16. Klenerman, P., and R.M. Zinkernagel. 1998. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature. 394:482-485.
17. Tissot, A.C., C. Ciatto, P.R. Mittl, M.G. Grutter, and A. Pluckthun. 2000. Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J. Mol. Biol. 302:873-885.
18. Gairin, J.E., and M.B. Oldstone. 1992. Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: Implications for control of viral disease. J. Virol. 66:6755-6762.
19. + T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 7:795-800.
20. Battegay, M., S. Cooper, A. Althage, J. Baenziger, H. Hengartner, and R.M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods. 33:191-198 (erratum published 35:115 and 38:263).
21. Ciurea A., P. Klenerman, L. Hunziker, E. Horvath, B. Odermatt, A.F. Ochsenbein, H. Hengartner, and R.M. Zinkernagel. 1999. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc. Natl. Acad. Sci. USA. 96:11964-11969.
22. Oxenius, A., M.F. Bachmann, R.M. Zinkernagel, and H. Hengartner. 1998. Virus-specific MHC class II-restricted TCR-transgenic mice: Effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28:390-400.
23. Ou, R., S. Zhou, L. Huang, and D. Moskophidis. 2001. Critical role for α/β and γ interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J. Virol. 75:8407-8423.
24. Ehl, S., J. Hombach, P. Aichele, H. Hengartner, and R.M. Zinkernagel. 1997. Bystander activation of cytotoxic T cells: Studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J. Exp. Med. 185:1241-1251.
25. Oxenius, A., M.F. Bachmann, D. Mathis, C. Benoist, R.M. Zinkernagel, and H. Hengartner. 1997. Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection. J. Immunol. 158:5717-5726.
26. + T cells upon acute versus persistent viral infection. Immunity. 9:449-457.
27. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193:297-306.
28. + T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 187:1903-1920.
29. Kamperschroer, C., and D.G. Quinn. 2002 The role of proinflammatory cytokines in wasting disease during lymphocytic choriomeningitis virus infection. J. Immunol. 169:340-349.